Marc Davies

Vice President of R&D • Leucid Bio

Marc Davies received his PhD from the laboratory of Dr John Maher at King’s College London, where his research focussed on the development and pre-clinical assessment of CAR T-cells targeting the extended ErbB family. This product is now under investigation in an investigator-led Phase I clinical trial for patients with relapsed/refractory head and neck cancer. Following a post-doctoral position at University College London developing CAR T-cells for haematological malignancies, Marc returned to KCL where his research focussed on enhancing CAR T-cell efficacy against solid tumours. With over 15 years of experience in the field of adoptive cell therapy, Marc joined Leucid Bio in May 2021 as VP of CAR Engineering to manage their burgeoning CAR T-cell R&D pipeline and clinical translation of their lead asset, LEU011.

Also speaking

Thomas Bols

Head of Government Affairs and Patient Advocacy, EMEA • PTC Therapeutics

Michal Besser

CTO, Davidoff Cancer Center • Rabin Medical Center

Alexander Natz

Secretary General • EUCOPE

Event Info


Event Brochure

Take a look at the 2023 Event Brochure for Advanced Therapies Europe.

Download the 2023 Speaker List

Download the 2023 Speaker List for Advanced Therapies Europe here.